Acute myeloid leukemia: 2019 update on risk-stratification and management

作者：Estey, Elihu H.^*

来源：American Journal of Hematology, 2018, 93(10): 1267-1291.

DOI：10.1002/ajh.25214

• MINIMAL RESIDUAL DISEASE
• STEM-CELL TRANSPLANTATION
• RANDOMIZED PHASE-III
• HIGH-DOSE CYTARABINE
• GEMTUZUMAB OZOGAMICIN MYLOTARG
• 1ST COMPLETE REMISSION
• NEWLY-DIAGNOSED AML
• TERM-FOLLOW-UP
• OLDER PATIENTS
• INTENSIVE CHEMOTHERAPY

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason patients are not cured is resistance to treatment, often manifested as relapse from remission, rather than, even in older patients, TRM, whose incidence is decreasing. Knowledge of the pre-treatment mutation status of various genes has improved our ability to assign initial treatment and, of particular importance, knowledge of whether patients ostensibly in remission have measurable residual disease should influence subsequent management. Several new drugs have been approved by the FDA and we discuss their role in treatment.

• 出版日期2018-10